North America Medical Writing Market Report by Type, Application, End Use, Countries and Company Analysis, 2026-2034

North America Medical Writing Industry Size and Forecast

North America Medical Writing Industry will grow from US$ XX Billion in 2025 to US$ XX Billion by 2034, registering a Compound Annual Growth Rate (CAGR) of XX% from 2026 to 2034. Growth is supported by increasing pharmaceutical and biotechnology research, rising clinical trial activity, expanding regulatory submissions, and growing demand for accurate scientific documentation. Medical writing services are increasingly used for clinical study reports, regulatory documents, manuscripts, protocols, and safety reports, while outsourcing enables life-sciences companies to access specialized expertise efficiently.

What is Medical Writing and Its Uses & Popularity in North America

Medical writing is the specialized preparation of scientific, clinical, regulatory, and healthcare-related documents for pharmaceutical companies, biotechnology firms, medical-device manufacturers, contract research organizations (CROs), healthcare institutions, and academic organizations. Its applications include clinical study reports, clinical-trial protocols, investigator brochures, regulatory submissions, common technical documents, safety reports, scientific manuscripts, medical education materials, and publication content. North America is a major global center for medical writing because of its large pharmaceutical and biotechnology ecosystem, extensive clinical-research infrastructure, and stringent regulatory requirements. Clinical writing represented the leading service category, while regulatory writing is among the faster-growing areas. The United States generates particularly strong demand because companies must prepare extensive, accurate documentation for FDA review. Growing outsourcing to specialist medical-writing agencies and CROs is also increasing market adoption, enabling life-sciences companies to access specialized expertise while managing expanding documentation requirements.

Pharmaceutical and Biotechnology R&D Expenditure by Top Companies

Leading Companies by R&D Investment

• Merck & Co. – Invested approximately US$15.8 billion in R&D in 2025, representing about 24.3% of revenue. R&D spending declined 12% from 2024, partly reflecting lower business-development charges.
• Roche – Reported approximately US$14.3 billion in 2025 R&D expenditure, equivalent to around 18% of revenue, maintaining substantial investment across pharmaceuticals and diagnostics.
• Johnson & Johnson – Allocated approximately US$14.7 billion to R&D in 2025, around 16% of revenue, supporting pharmaceutical and medical-technology innovation.
• AstraZeneca – Spent approximately US$14.2 billion on R&D in 2025, equivalent to about 24% of revenue, with investment supporting its oncology, cardiovascular, respiratory, immunology, and rare-disease pipeline.
• Eli Lilly – R&D expenditure reached approximately US$13.3 billion in 2025, increasing about 21% year over year and representing roughly 20% of revenue.
• Novartis – Invested approximately US$11.2 billion in R&D in 2025, or about 21% of revenue, reflecting continued focus on innovative medicines and pipeline expansion.
• Pfizer – Reported approximately US$10.2 billion in R&D spending in 2025, representing around 16% of revenue.
• Bristol Myers Squibb – Allocated approximately US$10.0 billion to R&D in 2025, equal to roughly 21% of revenue, supporting research in oncology, immunology, cardiovascular disease, and other areas.
• AbbVie – Spent approximately US$9.1 billion on R&D in 2025, equivalent to around 15% of revenue.
• Sanofi – Invested approximately US$9.1 billion in R&D during 2025, representing around 18% of revenue and reflecting continued investment in innovative medicines and vaccines.

Growth Drivers of the North America Medical Writing Industry

Expansion of Pharmaceutical and Biotechnology R&D

Increasing pharmaceutical and biotechnology research activity is a fundamental driver of medical writing demand in North America. Drug developers require extensive documentation throughout discovery, preclinical development, clinical trials, regulatory submission, and post-marketing activities. Medical writers translate complex scientific and clinical information into structured documents that satisfy regulatory and scientific requirements. The scale of U.S. biopharmaceutical research provides a substantial demand base. A study cited by PhRMA estimated that global biopharmaceutical companies invested US$276 billion in R&D in 2021, with U.S.-headquartered companies responsible for 55% of worldwide biopharmaceutical R&D investment. The continued development of biologics, oncology therapies, rare-disease treatments, vaccines, and personalized medicines generates additional documentation requirements. In 2025, the FDA’s CDER approved 46 novel drugs, highlighting the continuing flow of new therapies requiring regulatory and scientific documentation. As pharmaceutical pipelines become more complex, companies increasingly use specialist medical writers and CRO partners to prepare submissions, clinical reports, publications, and safety documentation efficiently.

Rising Clinical-Trial and Regulatory Documentation Requirements

Growing clinical-development activity and increasingly detailed regulatory requirements are strengthening demand for medical writing services. Clinical development generates large volumes of documents, including protocols, investigator brochures, informed-consent materials, clinical study reports, statistical summaries, safety narratives, and regulatory submissions. The U.S. FDA received 319,828 CDER submissions in 2025, compared with 310,433 in 2024, according to its electronic submission statistics. The FDA also approved 46 novel drugs in 2025, demonstrating the substantial regulatory workload associated with new therapies. Medical writers help sponsors organize complex scientific evidence into standardized and regulator-ready documentation while maintaining consistency across large development programs. Increasing development of advanced therapies, biologics, orphan drugs, and precision medicines can further increase documentation complexity. Regulatory writing is therefore becoming an important specialization within the industry. Pharmaceutical and biotechnology companies can also outsource documentation activities to CROs and specialist providers, allowing internal scientific teams to concentrate on research and development while external experts manage documentation, editing, submission preparation, and publication workflows.

Increasing Outsourcing to CROs and Specialist Medical-Writing Providers

Outsourcing is another important factor supporting the North American medical writing industry. Pharmaceutical and biotechnology companies increasingly use CROs and specialized medical-communications organizations to handle documentation requirements associated with clinical development, regulatory submissions, publications, and medical education. Outsourcing provides access to experienced writers and subject-matter specialists while allowing companies to scale documentation teams according to project requirements. Grand View Research identifies rising CRO outsourcing and increased R&D investment among the principal factors supporting medical writing market growth. North America accounted for 36.1% of global medical writing revenue in 2025, reflecting the region’s concentration of pharmaceutical companies, biotechnology firms, CROs, and regulatory activities. The outsourcing model is particularly useful for smaller biotechnology companies that may not maintain large internal medical-writing departments. Increasing specialization in regulatory, clinical, scientific, and publication writing is also encouraging companies to use multiple external providers. At the same time, technology-enabled collaboration and AI-assisted document workflows are creating opportunities to improve productivity while maintaining human scientific and regulatory oversight.

Challenges of the North America Medical Writing Industry

Shortage of Specialized and Experienced Medical Writers

The requirement for highly specialized expertise can create a workforce challenge for the North American medical writing industry. Effective medical writers must combine strong scientific and communication skills with knowledge of clinical research, statistics, regulatory requirements, therapeutic areas, and document standards. The complexity increases for biologics, gene therapies, cell therapies, oncology products, rare diseases, and advanced clinical-trial designs. Companies therefore need writers capable of understanding highly technical evidence while producing concise and regulator-compliant documents. Demand is also increasing as pharmaceutical and biotechnology pipelines expand. The FDA’s 319,828 CDER submissions in 2025 illustrate the scale of regulatory documentation handled by the U.S. drug-development system. Attracting and retaining experienced writers can consequently increase operating costs for service providers and life-sciences organizations. Training new writers requires substantial time because they must develop both therapeutic-area knowledge and familiarity with regulatory documentation standards. Competition for experienced professionals can also encourage outsourcing providers to expand geographically or use technology-assisted workflows to increase capacity.

Increasing Document Complexity and Quality-Control Requirements

Growing complexity in clinical research and regulatory submissions creates another challenge for medical writing companies. Modern development programs can involve large datasets, multiple study populations, complex endpoints, advanced therapies, and extensive safety information. Writers must accurately interpret information from clinical, statistical, pharmacological, and regulatory teams while maintaining consistency across numerous documents. Errors or inconsistencies can result in additional review cycles and potentially delay submissions. The scale of regulatory activity illustrates the workload: FDA electronic submission statistics recorded 7.52 million total submissions across FDA centers in 2025, including more than 319,800 CDER submissions and approximately 97,100 CBER submissions. At the same time, growing use of AI-assisted writing tools introduces additional requirements for verification, source checking, confidentiality, and human oversight. Medical-writing organizations must therefore balance productivity improvements with rigorous quality assurance. Maintaining document accuracy, regulatory compliance, data integrity, version control, and consistency across global submissions remains resource-intensive, particularly for complex clinical programs involving multiple therapeutic areas and regulatory jurisdictions.

Medical Writing and Medical-Writing Technology Launches Worldwide

• NEXT Medical Writing Automation – Indegene, 2025: Indegene launched NEXT Medical Writing Automation in July 2025, combining generative AI with medical-writing expertise to accelerate clinical-development and regulatory-document creation. The platform uses Indegene’s Cortex AI engine and targets high-quality, compliant documentation.
• CoAuthor Regulatory Writing Software – Certara, 2024: Certara launched the next generation of CoAuthor in June 2024. The GenAI-enabled platform combines document templates, Microsoft Word integration, structured content authoring, and a life-sciences-focused AI environment to support regulatory and medical writers.
• MACg Medical Affairs Content Generator – AINGENS, 2025: AINGENS introduced MACg in January 2025 as an AI-powered medical writing, research, and reference-management assistant. The platform supports AI writing, PubMed searches, literature summarization, editing, reference management, and citation workflows for life-sciences users.
• Cortex Generative AI Platform – Indegene, 2025: Indegene launched Cortex in February 2025 as a life-sciences-specific GenAI platform. Its applications include improving medical writing, streamlining content supply chains, and accelerating medical-legal-regulatory reviews through knowledge engineering and configurable AI agents.
• EVERSANA ORCHESTRATE MLR – EVERSANA, 2025: EVERSANA launched ORCHESTRATE MLR in April 2025, an AI-powered platform designed to streamline medical, legal, and regulatory review. The company stated that the platform can automate 90% of common MLR review tasks, supporting faster content approval workflows.
• CAPTIS CMC Module 3 Automation – Celegence, 2025: Celegence announced in July 2025 that its CAPTIS platform had successfully automated creation of CMC Module 3 documentation using generative AI. The development was demonstrated through a pilot with Kenvue and targets pharmaceutical regulatory-writing workflows.
• AI Medical Writer – Arist, 2025: Arist launched an AI Medical Writer in September 2025 as part of its AI Creator platform. The tool researches academic sources and verified documents, generates medical-training content, provides inline citations, and supports review and validation by medical professionals.
• QInscribe AI Medical Writing Service – 2025: QInscribe officially launched in September 2025 as a medical-writing services brand focused on AI-supported regulatory writing, scientific writing, and clinical-trial transparency. The company reported that its GenAI workflow can reduce the time required to generate a draft clinical study report by 90%.
• Sesen Life-Sciences Language and AI Solutions – 2025: Sesen launched in June 2025 as a specialized language-services company for pharmaceutical, biotechnology, medical-device, CRO, and regulatory organizations. Its SesenGPT platform supports AI-enhanced linguistic workflows across medical and regulatory content in 150+ languages.
• eVa AI Agent – Viseven, 2025: Viseven launched eVa in July 2025 as an AI agent for pharmaceutical and life-sciences marketing and medical teams. The platform generates content layouts, connects with digital-asset-management systems, and performs pre-checks to support compliant medical-legal-regulatory workflows.

Growing Clinical Documentation Requirements

North America clinical medical writing market is supported by extensive clinical research, pharmaceutical development, and regulatory activity across the United States and Canada. Clinical medical writers prepare protocols, investigator brochures, clinical study reports (CSRs), statistical analysis plans, patient-facing documents, and other materials required throughout the clinical-development lifecycle. In the United States, the FDA recorded 319,828 CDER submissions in 2025, compared with 310,433 in 2024, highlighting the substantial volume of regulatory documentation generated by the pharmaceutical industry. The FDA also approved 46 novel drugs in 2025, creating continued requirements for clinical and regulatory documentation supporting drug approvals. Growing development of biologics, cell and gene therapies, precision medicine, and complex trial designs is increasing the need for specialized writers who can interpret sophisticated clinical data. Pharmaceutical and biotechnology companies are also outsourcing documentation activities to specialist providers and CROs to improve scalability, consistency, and regulatory compliance, supporting continued demand for clinical medical writing services across North America.

Expanding Biomedical Research Output

Scientific medical writing is gaining importance across North America as pharmaceutical companies, universities, hospitals, biotechnology firms, and research organizations generate increasing volumes of scientific evidence. Scientific writers develop manuscripts, abstracts, conference presentations, review articles, white papers, grant proposals, and research summaries that translate complex findings into clear scientific communication. The scale of U.S. biomedical research provides a substantial foundation for this segment. NIH awarded US$35.3 billion in extramural grants during FY2025, supporting research at universities, hospitals, small businesses, and other organizations. NIH research-project-grant applications also reached 62,592 in FY2025, up 12.9% from 55,418 in FY2024. This large research ecosystem creates recurring requirements for publication support, scientific editing, data interpretation, and grant-related writing. Growth in digital publishing, open-access dissemination, and multidisciplinary research is further increasing demand for professional scientific communication. Medical writers help researchers convert highly technical findings into structured, publication-ready content for scientific audiences and broader healthcare stakeholders.

Rising Demand for Accessible Health Information

Medical journalism writing represents a specialized part of the North American medical writing industry, focusing on communicating healthcare and scientific information to patients, consumers, and general audiences. Writers produce health articles, news stories, newsletters, blogs, feature reports, and educational content covering diseases, treatments, clinical research, prevention, and public health. Demand is supported by the enormous volume of medical research and regulatory activity in the region, which creates a continuing need to translate technical developments into accessible language. The FDA recorded more than 7.5 million electronic submissions across its centers in 2025, demonstrating the scale of information generated within the U.S. health-product ecosystem. Medical journalism also benefits from growing digital health platforms, healthcare websites, online publications, and institutional communication channels. During major public-health events, the need for accurate interpretation of scientific evidence becomes particularly important. Professional medical journalists therefore serve as an intermediary between researchers, clinicians, healthcare organizations, media outlets, and the public, supporting evidence-based health education.

Increasing Outsourcing to CROs and Specialist Providers

Contract research organizations (CROs), specialist medical-writing companies, independent writers, and boutique consultancies represent an important component of the North American medical writing market. Pharmaceutical and biotechnology companies increasingly outsource clinical, scientific, and regulatory documentation to external providers to obtain specialized expertise while managing internal resources efficiently. CROs can support multiple stages of development, including clinical protocols, investigator brochures, clinical study reports, regulatory submission documents, safety reports, and publication planning. The scale of pharmaceutical research creates a significant addressable workload: NIH alone distributed US$35.3 billion in extramural biomedical research funding in FY2025, while research-project-grant funding reached US$26.5 billion. External providers can help organizations handle fluctuating workloads, specialized therapeutic areas, tight submission schedules, and evolving regulatory requirements. Demand is also supported by complex biologics and advanced therapies that require writers with scientific and regulatory expertise. As life-sciences companies increasingly use flexible operating models, CROs and independent medical-writing specialists are positioned to remain important suppliers across North America.

United States Strong Pharmaceutical and Regulatory Activity

United States represents the largest national market within North America for medical writing, supported by its extensive pharmaceutical, biotechnology, clinical research, and academic ecosystems. Medical writers contribute to clinical protocols, regulatory submissions, clinical study reports, scientific publications, safety documentation, and patient education materials. The scale of FDA activity illustrates the documentation requirements facing drug developers. CDER received 319,828 electronic submissions in 2025, up from 310,433 in 2024.During 2025, CDER also approved 46 novel drugs, including therapies spanning oncology, rare diseases, neurological disorders, infectious diseases, and other therapeutic areas. :chatgpt-content-reference{index=“6”} In addition, NIH provided US$35.3 billion in extramural research grants during FY2025, supporting thousands of biomedical research organizations. These activities sustain demand for clinical, scientific, and regulatory writers. The growing complexity of biologics, precision medicine, gene therapies, and data-rich clinical programs further increases the need for specialized professionals capable of converting technical evidence into compliant, clearly structured documentation.

Canada Expanding Pharmaceutical R&D and Clinical Documentation

Canada’s medical writing market is supported by pharmaceutical research, biotechnology development, clinical trials, academic research, and Health Canada’s regulatory framework. In 2024, Canadian pharmaceutical business R&D expenditure reached approximately C$1.295 billion, up from C$1.069 billion in 2023, according to Canada’s pharmaceutical-sector profile. The PMPRB reported that 70.2% of applied pharmaceutical R&D expenditure in 2024 was associated with Phase I–III clinical trials, emphasizing the importance of clinical documentation throughout drug development. Health Canada requires sponsors conducting most clinical trials to submit clinical trial applications and follow good clinical-practice requirements. Its current framework also emphasizes electronic regulatory submissions, including eCTD formats for applicable activities. These requirements create demand for clinical protocols, regulatory documents, study reports, scientific publications, and patient-facing materials. In addition, Health Canada’s 2026 guidance on clinical-trial registration and results disclosure reinforces the importance of clear, structured, and transparent clinical information.